Tick-transmitted brain disease may be treatable
Researchers have found antibodies capable of neutralising tick-borne encephalitis (TBE), a viral infectious disease transmitted by tick bites. Described in the Journal of Experimental Medicine, these so-called broadly neutralising antibodies have shown promise in preventing TBE in mice, could inform the development of better vaccines for humans and may even be able to treat the condition.
Once bitten by an infected tick, some TBE patients develop flu-like symptoms that resolve quietly but leave behind rampant neurological disease — brain swelling, memory loss and cognitive decline. Cases are on the rise in Central Europe and Russia, with some 10,000 incidents reported each year. Vaccines can provide protection, but only for a limited time. There is no cure.
The new study saw researchers from the laboratory of Michel C Nussenzweig at New York’s Rockefeller University, led by Marianna Agudelo, examine nearly 800 antibodies obtained from individuals who had recovered from TBE or had been vaccinated to prevent infection. The most potent antibodies, designated VH3-48, turned out to be best suited to fend off future infections. They found that VH3-48 neutralised lab-grown varieties of the TBE virus, as well other tick-borne illnesses including the Langat, Louping-ill, Omsk hemorrhagic fever, Kyasanur forest disease and Powassan viruses.
The researchers also showed that these powerful antibodies are not common; in fact, most of the antibodies produced by humans exposed to TBE virus are of inferior quality, with the coveted VH3-48 antibodies making only occasional appearances. Moreover, vaccinated patients in the study did not manage to develop any VH3-48 antibodies at all.
“You’d expect the most prevalent antibodies to be the absolute best, but that is not what we found in TBE,” Agudelo said. “This may explain how the virus tricks the immune system, misdirecting it into producing inferior antibodies.”
The discovery of VH3-48 provides hope for a more effective TBE vaccine. Current vaccines require three doses spaced over two years and only provide about five years of protection before a booster shot is required. Next-generation vaccines built around coaxing the body into producing the rare VH3-48 antibody could be more potent, require fewer booster shots and prove protective against a number of tick-borne viruses.
“A vaccine like this would not just be more elegant, but also better focused,” Nussenzweig said. “Now that we have the structures of these antibodies, we know what to target in order to design more effective vaccines.”
Broadly neutralising antibodies may also provide the first specific treatment for TBE. Nussenzweig, Agudelo and colleagues found that mice infected with TBE recover after receiving antibody therapy, although it remains to be seen if this finding will translate to humans.
“The next step is a clinical trial with the antibodies, perhaps in Europe where there are many cases, to see whether we can ameliorate the symptoms of those suffering from encephalitis,” Nussenzweig said.
Materials technology company Xefco has developed a groundbreaking antiviral technology that has...
Researchers have created medical gowns for healthcare workers and first responders using paper...
Astronauts aboard the International Space Station are conducting experiments with an...